Why the Next Billion Dollar Longevity Opportunity May Not Be a Product

TalentNewsletter newsroom brief · 4h ago · 1 min read · via entrepreneur.com

Longevity has no shortage of products, science, capital or consumer interest. The bottleneck is translation: getting promising science validated, understood by clinicians, implemented responsibly and ultimately to patients. This story matters for Business & Startups readers tracking talent. Reported by entrepreneur.com. Read the full original at the source link below.

Originally reported by entrepreneur.com. TalentNewsletter curates and briefs the business & startups stories that matter. Our editorial policy →

Across the eCorp newsroom network

StartupNews — This Doctor Runs a $2.3 Billion Health Startup. He Says This Is Why Walmart and IBM Couldn’t Crack Healthcare.
OfficeNewsletter — This 23-Year-Old Turned a Facebook Marketplace Find Into a Creative Household Product. It Exploded on Social Media and Made $150K in 2 Weeks.
EcomNews — A Crisis Expert Says the Company Caught in the Coldplay Kiss Cam Scandal Responded Right — 48 Hours Too Late. Here’s How to Avoid the Same Mistake.
StartupNews — He Joined Citadel in 1994 With No Trading Experience and Helped Build It to $10 Billion. He Credits His Success to This Mindset.

Why the Next Billion Dollar Longevity Opportunity May Not Be a Product

More from TalentNewsletter

Across the eCorp newsroom network